A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) | MicrobiomeTrials← Back to trialsNCT06282159
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-02-23Est. Completion: 2025-07-28
Enrollment target: 65 participants Locations- Clinical Study Site, Phoenix, Arizona, United States
- Clinical Study Site, Irvine, California, United States
- Clinical Study Site, Stamford, Connecticut, United States
- Clinical Study Site, Boca Raton, Florida, United States
- Clinical Study Site, Bradenton, Florida, United States
- Clinical Study Site, Maitland, Florida, United States
- Clincal Study Site, Tampa, Florida, United States
- Clinical Study Site, O'Fallon, Illinois, United States
- Clinical Study Site, Kansas City, Kansas, United States
- Clinical Study Site, Lexington, Kentucky, United States
- Clinical Study Site, Boston, Massachusetts, United States
- Clinical Study Site, East Lansing, Michigan, United States
- Clinical Study Site, Columbia, Missouri, United States
- Clinical Study Site, Cincinnati, Ohio, United States
- Clinical Study Site, Columbus, Ohio, United States
- Clinical Study Site, Dallas, Texas, United States
- Clinical Study Site, Dallas, Texas, United States
Other microbiome trials you might be interested in
Myasthenia Gravis
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with…
Paradise Valley, United StatesEst. completion Nov 17, 2023
Congenital Myasthenic SyndromeCMS
The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenit…
Sacramento, United StatesEst. completion Aug 24, 2027
Clinical Study Site #2, Houston, Texas, United StatesClinical Study Site, Houston, Texas, United StatesClinical Study Site, Lubbock, Texas, United StatesClinical Study Site, Richmond, Virginia, United StatesClinical Study Site, San Miguel de Tucumán, Tucumán Province, ArgentinaClinical Study Site, Buenos Aires, ArgentinaClinical Study Site, Buenos Aires, ArgentinaClinical Study Site, Buenos Aires, ArgentinaClinical Study Site, Córdoba, ArgentinaClinical Study Site, Rosario, ArgentinaClinical Study Site, London, Ontario, CanadaClinical Study Site, Ostrava, CzechiaClinical Study Site, Copenhagen, DenmarkClinical Study Site, Bordeaux, FranceClinical Study Site, Nice, FranceClinical Study Site, Strasbourg, FranceClinical Study Site, Haifa, IsraelClinical Study Site, Ramat Gan, IsraelClinical Study Site, Safed, IsraelClinical Study Site, Milan, ItalyClinical Study Site, Naples, ItalyClinical Study Site, Pisa, ItalyClinical Study Site, Rome, ItalyClinical Study Site, Rome, ItalyClinical Study Site, Amsterdam, NetherlandsClinical Study Site, Skopje, North MacedoniaClinical Study Site, Bergen, NorwayClinical Study Site, Bydgoszcz, PolandClinical Study Site, Katowice, PolandClinical Study Site, Krakow, PolandClinical Study Site, Krakow, PolandClinical Study Site, Lublin, PolandClinical Study Site, Warsaw, PolandClinical Study Site, Warsaw, PolandClinical Study Site, Belgrade, SerbiaClinical Study Site, Kragujevac, SerbiaClinical Study Site, Niš, SerbiaClinical Study Site, Novi Sad, SerbiaClinical Study Site, Malmö, Sweden